Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations with the Classical Mutation Pattern

Abstract

Patients with complex EGFR mutations with the classical mutation pattern had the same response rate, progression-free survival duration, and overall survival time as those with single classical mutations. EGFR TKIs may be the choice of treatment for this type of lung adenocarcinoma.